<li>abciximab<p>aspirin, abciximab.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>acebutolol<p>acebutolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of acebutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>aceclofenac<p>aceclofenac and aspirin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aceclofenac and aspirin both increase  serum potassium. Use Caution/Monitor.</p></li><li>acemetacin<p>acemetacin and aspirin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>acemetacin and aspirin both increase  serum potassium. Use Caution/Monitor.</p></li><li>acetazolamide<p>acetazolamide, aspirin.
Either increases levels of the other by Other (see comment). Use Caution/Monitor. 
Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.<span><br><br></span>acetazolamide, aspirin. Mechanism: passive renal tubular reabsorption due to increased pH. Use Caution/Monitor. Salicylate levels increased at moderate doses; risk of CNS toxicity. Salicylate levels decreased at large doses (d/t increased renal excretion of unchanged salicylic acid).</p></li><li>agrimony<p>aspirin and agrimony both increase  anticoagulation. Use Caution/Monitor.</p></li><li>albuterol<p>aspirin increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>alfalfa<p>aspirin and alfalfa both increase  anticoagulation. Use Caution/Monitor.</p></li><li>alfuzosin<p>aspirin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>alteplase<p>aspirin, alteplase.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>american ginseng<p>aspirin and american ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>amiloride<p>amiloride and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>amoxicillin<p>amoxicillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>amoxicillin, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>ampicillin<p>ampicillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.</p></li><li>anagrelide<p>aspirin, anagrelide.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; increases risk of bleeding; monitor closely.<span><br><br></span>anagrelide, aspirin.
Either increases toxicity of the other by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; increases risk of bleeding; monitor closely.</p></li><li>antithrombin alfa<p>antithrombin alfa and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, antithrombin alfa.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>antithrombin iii<p>antithrombin iii and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, antithrombin iii.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>apixaban<p>aspirin and apixaban both increase  anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (&lt;100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if  treated concomitantly with low-dose aspiriin. Avoid coadministration with chronic use of higher dose aspirin. In 1 trial (APPRAISE-2), therapy was terminated because of significantly increased bleeding when apixaban was administered with dual antiplatelet therapy (eg, aspirin plus clopidogrel) compared with single antiplatelet treatment</p></li><li>arformoterol<p>aspirin increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>argatroban<p>argatroban and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, argatroban.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>asenapine<p>aspirin decreases effects of asenapine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>atenolol<p>atenolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of atenolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>azficel-t<p>azficel-t, aspirin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking aspirin may experience increased bruising or bleeding at biopsy and/or injection sites. Concomitant use of aspirin is not recommended. .</p></li><li>azilsartan<p>aspirin, azilsartan.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.<span><br><br></span>aspirin decreases effects of azilsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.</p></li><li>bambuterol<p>aspirin increases and bambuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>bemiparin<p>bemiparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>benazepril<p>benazepril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals.</p></li><li>bendroflumethiazide<p>aspirin increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>betaxolol<p>betaxolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of betaxolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>bisoprolol<p>bisoprolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of bisoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>bivalirudin<p>bivalirudin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, bivalirudin.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>brinzolamide<p>brinzolamide, aspirin.
Either increases levels of the other by Other (see comment). Use Caution/Monitor. 
Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.</p></li><li>bumetanide<p>aspirin increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of bumetanide by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>candesartan<p>candesartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of candesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>candesartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>captopril<p>captopril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, elderly or volume depleted individuals.</p></li><li>carbenoxolone<p>aspirin increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>carvedilol<p>carvedilol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of carvedilol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>celecoxib<p>aspirin and celecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and celecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>celiprolol<p>celiprolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of celiprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>chlorothiazide<p>aspirin increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>chlorpropamide<p>aspirin increases effects of chlorpropamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>chlorthalidone<p>aspirin increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>aspirin and choline magnesium trisalicylate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor.</p></li><li>cilostazol<p>aspirin, cilostazol.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>cinnamon<p>aspirin and cinnamon both increase  anticoagulation. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>aspirin decreases levels of ciprofloxacin by Other (see comment). Use Caution/Monitor. 
Comment: Buffered aspirin may decrease absorption of quinolones. Consider administering 2 hr before or 6 hr after, buffered aspirin administration.</p></li><li>citalopram<p>citalopram, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. If possible, avoid concurrent use.</p></li><li>clobetasone<p>aspirin, clobetasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>clomipramine<p>clomipramine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. Clomipramine inhib. serotonin uptake by platelets.</p></li><li>clopidogrel<p>aspirin, clopidogrel.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>collagenase clostridium histolyticum<p>aspirin increases toxicity of collagenase clostridium histolyticum by anticoagulation. Use Caution/Monitor. Collagenase clostridium histolyticum has high incidence of ecchymosis/contusion at injection site; avoid concomitant anticoagulants (except for low-dose aspirin, ie, up to 150 mg/day).</p></li><li>cordyceps<p>aspirin and cordyceps both increase  anticoagulation. Use Caution/Monitor.</p></li><li>cortisone<p>aspirin, cortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>cyclopenthiazide<p>aspirin increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dabigatran<p>dabigatran and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (&lt;100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if treated concomitantly with low-dose aspirin. Avoid coadministration with chronic use of higher dose aspirin</p></li><li>dalteparin<p>dalteparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, dalteparin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>deferasirox<p>deferasirox, aspirin. Other (see comment). Use Caution/Monitor. 
Comment:  Combination may increase GI bleeding, ulceration and irritation. Use with caution.</p></li><li>defibrotide<p>defibrotide increases effects of aspirin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Defibrotide may enhance effects of platelet inhibitors.</p></li><li>deflazacort<p>aspirin, deflazacort.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>desirudin<p>aspirin, desirudin.
Either increases levels of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>dexamethasone<p>aspirin, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>diclofenac<p>aspirin and diclofenac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and diclofenac both increase  serum potassium. Use Caution/Monitor.</p></li><li>dicloxacillin<p>dicloxacillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.</p></li><li>diflunisal<p>aspirin and diflunisal both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and diflunisal both increase  serum potassium. Use Caution/Monitor.</p></li><li>digoxin<p>aspirin and digoxin both increase  serum potassium. Use Caution/Monitor.</p></li><li>dipyridamole<p>aspirin, dipyridamole.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>divalproex sodium<p>aspirin increases levels of divalproex sodium by plasma protein binding competition. Use Caution/Monitor.</p></li><li>dobutamine<p>aspirin increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>dong quai<p>aspirin and dong quai both increase  anticoagulation. Use Caution/Monitor.</p></li><li>dopexamine<p>aspirin increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>doxazosin<p>aspirin decreases effects of doxazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>drospirenone<p>drospirenone and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>duloxetine<p>duloxetine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>edoxaban<p>edoxaban, aspirin.
Either increases toxicity of the other by anticoagulation. Modify Therapy/Monitor Closely. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (&lt;100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if treated concomitantly with low-dose aspirin. Avoid coadministration with chronic use of higher dose aspirin.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df, aspirin.
Either increases toxicity of the other by decreasing renal clearance. Modify Therapy/Monitor Closely. Toxicity may result from coadministration of emtricitabine and tenofovir with other drugs that are also primarily excreted by glomerular filtration and/or active tubular secretion including high-dose or multiple-dose NSAIDs; alternatives to NSAIDs should be considered.</p></li><li>enalapril<p>enalapril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals.</p></li><li>enoxaparin<p>enoxaparin and aspirin both increase  anticoagulation. Use Caution/Monitor. Additive effects are intended when both drugs are prescribed as indicated for unstable angina, non-Q-wave MI, and STEMI<span><br><br></span>aspirin, enoxaparin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>ephedrine<p>aspirin increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ephedrine (pulmonary)<p>aspirin increases and ephedrine (pulmonary) decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>epinephrine<p>aspirin increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epinephrine racemic<p>aspirin increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>epoprostenol<p>aspirin and epoprostenol both increase  anticoagulation. Use Caution/Monitor.</p></li><li>eprosartan<p>eprosartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of eprosartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>eprosartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>eptifibatide<p>aspirin, eptifibatide.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>escitalopram<p>escitalopram, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>esmolol<p>esmolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of esmolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>ethacrynic acid<p>aspirin increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>etodolac<p>aspirin and etodolac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and etodolac both increase  serum potassium. Use Caution/Monitor.</p></li><li>etoricoxib<p>aspirin and etoricoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and etoricoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>fenbufen<p>aspirin and fenbufen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and fenbufen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fennel<p>aspirin and fennel both increase  anticoagulation. Use Caution/Monitor.</p></li><li>fenoprofen<p>aspirin and fenoprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and fenoprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>feverfew<p>aspirin and feverfew both increase  anticoagulation. Use Caution/Monitor.</p></li><li>fish oil<p>fish oil, aspirin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking fish oil and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .</p></li><li>flucloxacillin<p>flucloxacillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>flucloxacillin, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>fludrocortisone<p>aspirin, fludrocortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fluoxetine<p>fluoxetine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>flurbiprofen<p>aspirin and flurbiprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and flurbiprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>fluvoxamine<p>fluvoxamine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>fondaparinux<p>fondaparinux and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>formoterol<p>aspirin increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>forskolin<p>aspirin and forskolin both increase  anticoagulation. Use Caution/Monitor.</p></li><li>fosinopril<p>fosinopril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals.</p></li><li>furosemide<p>aspirin increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>garlic<p>aspirin and garlic both increase  anticoagulation. Use Caution/Monitor.</p></li><li>gentamicin<p>aspirin increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ginger<p>aspirin and ginger both increase  anticoagulation. Use Caution/Monitor.</p></li><li>ginkgo biloba<p>aspirin and ginkgo biloba both increase  anticoagulation. Use Caution/Monitor.</p></li><li>glimepiride<p>aspirin increases effects of glimepiride by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glipizide<p>aspirin increases effects of glipizide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>gliquidone<p>aspirin increases effects of gliquidone by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>glyburide<p>aspirin increases effects of glyburide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>green tea<p>green tea increases effects of aspirin by pharmacodynamic synergism. Use Caution/Monitor. (Theoretical, due to caffeine content).   Combination may increase risk of bleeding.</p></li><li>griseofulvin<p>griseofulvin decreases levels of aspirin by unknown mechanism. Use Caution/Monitor.</p></li><li>heparin<p>heparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, heparin.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>horse chestnut seed<p>aspirin and horse chestnut seed both increase  anticoagulation. Use Caution/Monitor.</p></li><li>hyaluronidase<p>aspirin decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. 
Comment: Salicylates, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.</p></li><li>hydralazine<p>aspirin decreases effects of hydralazine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>hydrochlorothiazide<p>aspirin increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>hydrocortisone<p>aspirin, hydrocortisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>ibuprofen<p>aspirin and ibuprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and ibuprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>icosapent<p>icosapent, aspirin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Icosapent may prolong bleeding time; monitor periodically if coadministered with other drugs that affect bleeding.</p></li><li>imatinib<p>imatinib, aspirin.
Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. 
Comment: Imatinib may cause thrombocytopenia; bleeding risk increased when imatinib is   coadministered with anticoagulants, NSAIDs, platelet inhibitors, and thrombolytic agents.</p></li><li>indapamide<p>aspirin increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>indomethacin<p>aspirin and indomethacin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and indomethacin both increase  serum potassium. Use Caution/Monitor.</p></li><li>insulin aspart<p>aspirin increases effects of insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin aspart protamine/insulin aspart<p>aspirin increases effects of insulin aspart protamine/insulin aspart by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin degludec<p>aspirin increases effects of insulin degludec by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin degludec/insulin aspart<p>aspirin, insulin degludec/insulin aspart.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood glucose.</p></li><li>insulin detemir<p>aspirin increases effects of insulin detemir by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin glargine<p>aspirin increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin glulisine<p>aspirin increases effects of insulin glulisine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin inhaled<p>aspirin increases effects of insulin inhaled by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin isophane human/insulin regular human<p>aspirin increases effects of insulin isophane human/insulin regular human by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin lispro<p>aspirin increases effects of insulin lispro by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin lispro protamine/insulin lispro<p>aspirin increases effects of insulin lispro protamine/insulin lispro by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin nph<p>aspirin increases effects of insulin nph by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin regular human<p>aspirin increases effects of insulin regular human by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>irbesartan<p>irbesartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of irbesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>irbesartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment:  May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>isoproterenol<p>aspirin increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ketoprofen<p>aspirin and ketoprofen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and ketoprofen both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac<p>aspirin and ketorolac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and ketorolac both increase  serum potassium. Use Caution/Monitor.</p></li><li>ketorolac intranasal<p>aspirin and ketorolac intranasal both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and ketorolac intranasal both increase  serum potassium. Use Caution/Monitor.</p></li><li>labetalol<p>labetalol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of labetalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>lepirudin<p>lepirudin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.<span><br><br></span>aspirin, lepirudin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>levalbuterol<p>aspirin increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>levomilnacipran<p>levomilnacipran, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. SNRIs may further impair platelet activity in patients taking antiplatelet or anticoagulant drugs.</p></li><li>lisinopril<p>lisinopril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals.</p></li><li>lithium<p>aspirin increases levels of lithium by decreasing renal clearance. Use Caution/Monitor.</p></li><li>lornoxicam<p>aspirin and lornoxicam both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and lornoxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>losartan<p>losartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of losartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>losartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>meclofenamate<p>aspirin and meclofenamate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and meclofenamate both increase  serum potassium. Use Caution/Monitor.</p></li><li>mefenamic acid<p>aspirin and mefenamic acid both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and mefenamic acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>melatonin<p>melatonin increases effects of aspirin by anticoagulation. Use Caution/Monitor. Melatonin may decrease prothrombin time.</p></li><li>meloxicam<p>aspirin and meloxicam both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and meloxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>mesalamine<p>mesalamine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive nephrotoxicity.</p></li><li>metaproterenol<p>aspirin increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>methazolamide<p>methazolamide, aspirin.
Either increases levels of the other by Other (see comment). Use Caution/Monitor. 
Comment: Carbonic anhydrase inhibitors (CAIs) and salicylates inhibit each other's renal tubular secretion, resulting in increased plasma levels.  CAIs also shift salicylates from plasma to the CNS, leading to potential neurotoxicity.</p></li><li>methyclothiazide<p>aspirin increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  .</p></li><li>methylprednisolone<p>aspirin, methylprednisolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>metolazone<p>aspirin increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>metoprolol<p>metoprolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of metoprolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>milnacipran<p>milnacipran, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>mistletoe<p>aspirin increases and mistletoe decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>moexipril<p>moexipril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, in elderly or volume depleted individuals.</p></li><li>moxisylyte<p>aspirin decreases effects of moxisylyte by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>mycophenolate<p>aspirin will increase the level or effect of mycophenolate by  acidic (anionic) drug competition for renal tubular clearance. Use Caution/Monitor.</p></li><li>nabumetone<p>aspirin and nabumetone both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and nabumetone both increase  serum potassium. Use Caution/Monitor.</p></li><li>nadolol<p>nadolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of nadolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>nafcillin<p>nafcillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>nafcillin, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>naproxen<p>aspirin and naproxen both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and naproxen both increase  serum potassium. Use Caution/Monitor.</p></li><li>nebivolol<p>nebivolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of nebivolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>nefazodone<p>nefazodone, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>nettle<p>aspirin increases and nettle decreases anticoagulation. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>nitazoxanide<p>nitazoxanide, aspirin.
Either increases levels of the other by Mechanism: plasma protein binding competition. Use Caution/Monitor.</p></li><li>nitroglycerin rectal<p>aspirin will increase the level or effect of nitroglycerin rectal by  Other (see comment). Use Caution/Monitor. The pharmacological effects of nitroglycerin may be enhanced by concomitant administration of aspirin.</p></li><li>nitroglycerin sublingual<p>aspirin increases effects of nitroglycerin sublingual by additive vasodilation. Use Caution/Monitor. Vasodilatory and hemodynamic effects of NTG may be enhanced by coadministration with aspirin (additive effect desirable for emergent treatment).</p></li><li>norepinephrine<p>aspirin increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>olmesartan<p>olmesartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of olmesartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>olmesartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>omega 3 carboxylic acids<p>omega 3 carboxylic acids, aspirin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking omega-3 acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding.</p></li><li>omega 3 fatty acids<p>omega 3 fatty acids, aspirin. Other (see comment). Use Caution/Monitor. 
Comment: Patients taking omega-3-fatty acids and an anticoagulant or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding. .</p></li><li>ospemifene<p>aspirin, ospemifene.
Either increases levels of the other by plasma protein binding competition. Modify Therapy/Monitor Closely.</p></li><li>oxacillin<p>oxacillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>oxacillin, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>oxaprozin<p>aspirin and oxaprozin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and oxaprozin both increase  serum potassium. Use Caution/Monitor.</p></li><li>panax ginseng<p>aspirin and panax ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>parecoxib<p>aspirin and parecoxib both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and parecoxib both increase  serum potassium. Use Caution/Monitor.</p></li><li>paroxetine<p>paroxetine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>pau d'arco<p>aspirin and pau d'arco both increase  anticoagulation. Use Caution/Monitor.</p></li><li>pegaspargase<p>pegaspargase increases effects of aspirin by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of bleeding events.</p></li><li>penbutolol<p>penbutolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of penbutolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>penicillin g aqueous<p>penicillin g aqueous, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>penicillin g aqueous, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>perindopril<p>perindopril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high doses of aspirin,in elderly or volume depleted individuals.</p></li><li>phenindione<p>phenindione and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>phenoxybenzamine<p>aspirin decreases effects of phenoxybenzamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>phentolamine<p>aspirin decreases effects of phentolamine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>phytoestrogens<p>aspirin and phytoestrogens both increase  anticoagulation. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of pindolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>pirbuterol<p>aspirin increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>piroxicam<p>aspirin and piroxicam both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and piroxicam both increase  serum potassium. Use Caution/Monitor.</p></li><li>pivmecillinam<p>pivmecillinam, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>pivmecillinam, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>potassium acid phosphate<p>aspirin and potassium acid phosphate both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium chloride<p>aspirin and potassium chloride both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>potassium citrate<p>aspirin and potassium citrate both increase  serum potassium. Use Caution/Monitor.</p></li><li>prasugrel<p>aspirin, prasugrel.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>prazosin<p>aspirin decreases effects of prazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>prednisolone<p>aspirin, prednisolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>prednisone<p>aspirin, prednisone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>propranolol<p>propranolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of propranolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>protamine<p>protamine and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>quinapril<p>quinapril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high doses of aspirin, in elderly or volume depleted individuals.</p></li><li>ramipril<p>ramipril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high doses of aspirin, in elderly or volume depleted individuals.</p></li><li>reishi<p>aspirin and reishi both increase  anticoagulation. Use Caution/Monitor.</p></li><li>reteplase<p>aspirin, reteplase.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>rivaroxaban<p>aspirin, rivaroxaban.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. Both drugs have the potential to cause bleeding. The need for simultaneous use of low-dose aspirin (&lt;100 mg/day) with anticoagulants are common for patients with cardiovascular disease, but may result in increased bleeding; monitor closely. Promptly evaluate any signs or symptoms of blood loss if treated concomitantly with low-dose aspirin. Avoid coadministration with chronic use of higher dose aspirin.</p></li><li>rivastigmine<p>rivastigmine increases toxicity of aspirin by pharmacodynamic synergism. Use Caution/Monitor. Monitor patients for symptoms of active or occult gastrointestinal bleeding.</p></li><li>sacubitril/valsartan<p>sacubitril/valsartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>sacubitril/valsartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.<span><br><br></span>aspirin decreases effects of sacubitril/valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.</p></li><li>salicylates (non-asa)<p>aspirin and salicylates (non-asa) both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor.</p></li><li>salmeterol<p>aspirin increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>salsalate<p>aspirin and salsalate both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and salsalate both increase  serum potassium. Use Caution/Monitor.</p></li><li>saw palmetto<p>saw palmetto increases toxicity of aspirin by unspecified interaction mechanism. Use Caution/Monitor. May increase risk of bleeding.</p></li><li>sertraline<p>sertraline, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>siberian ginseng<p>aspirin and siberian ginseng both increase  anticoagulation. Use Caution/Monitor.</p></li><li>silodosin<p>aspirin decreases effects of silodosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>sodium picosulfate/magnesium oxide/anhydrous citric acid<p>aspirin, sodium picosulfate/magnesium oxide/anhydrous citric acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May be associated with fluid and electrolyte imbalances.</p></li><li>sotalol<p>sotalol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of sotalol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>spironolactone<p>spironolactone and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>succinylcholine<p>aspirin and succinylcholine both increase  serum potassium. Use Caution/Monitor.</p></li><li>sulfamethoxazole<p>aspirin, sulfamethoxazole.
Either increases effects of the other by plasma protein binding competition. Use Caution/Monitor. Due to high protein binding capacity of both drugs, one may displace the other when coadministered leading to an enhanced effect of the displaced drug; risk is low with low dose aspirin.</p></li><li>sulfasalazine<p>aspirin and sulfasalazine both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and sulfasalazine both increase  serum potassium. Use Caution/Monitor.</p></li><li>sulindac<p>aspirin and sulindac both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and sulindac both increase  serum potassium. Use Caution/Monitor.</p></li><li>telmisartan<p>telmisartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of telmisartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>telmisartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>temocillin<p>temocillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>temocillin, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>tenecteplase<p>aspirin, tenecteplase.
Either increases toxicity of the other by anticoagulation. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>terazosin<p>aspirin decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li><li>terbutaline<p>aspirin increases and terbutaline decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>ticagrelor<p>aspirin, ticagrelor. Other (see comment). Use Caution/Monitor. 
Comment: Maintenance doses of aspirin above 100 mg decreases effectiveness of ticagrelor. Therefore, after the initial loading dose of aspirin (usually 325 mg), use ticagrelor with a maintenance dose of aspirin of 75-100 mg.</p></li><li>ticarcillin<p>ticarcillin, aspirin.
Either increases levels of the other by plasma protein binding competition. Use Caution/Monitor.<span><br><br></span>ticarcillin, aspirin.
Either increases levels of the other by decreasing renal clearance. Use Caution/Monitor.</p></li><li>timolol<p>timolol and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (&gt;1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis.</p></li><li>tinzaparin<p>tinzaparin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely.</p></li><li>tirofiban<p>aspirin, tirofiban.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. The need for simultaneous use of low-dose aspirin and anticoagulant or antiplatelet agents are common for patients with cardiovascular disease; monitor closely.</p></li><li>tobramycin inhaled<p>tobramycin inhaled and aspirin both increase  nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Avoid concurrent or sequential use to decrease risk for ototoxicity</p></li><li>tolazamide<p>aspirin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolbutamide<p>aspirin increases effects of tolbutamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>tolfenamic acid<p>aspirin and tolfenamic acid both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and tolfenamic acid both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolmetin<p>aspirin and tolmetin both increase  anticoagulation. Use Caution/Monitor.<span><br><br></span>aspirin and tolmetin both increase  serum potassium. Use Caution/Monitor.</p></li><li>tolvaptan<p>aspirin and tolvaptan both increase  serum potassium. Use Caution/Monitor.</p></li><li>torsemide<p>aspirin increases and torsemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.</p></li><li>trandolapril<p>trandolapril, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly with high dose aspirin, in elderly and volume depleted.</p></li><li>trazodone<p>trazodone, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>triamcinolone<p>aspirin, triamcinolone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>triamterene<p>triamterene and aspirin both increase  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>valproic acid<p>aspirin increases levels of valproic acid by plasma protein binding competition. Use Caution/Monitor.</p></li><li>valsartan<p>valsartan and aspirin both increase  serum potassium. Use Caution/Monitor.<span><br><br></span>aspirin decreases effects of valsartan by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.  NSAIDs decrease synthesis of vasodilating renal prostaglandins, and thus affect fluid homeostasis and may diminish antihypertensive effect.<span><br><br></span>valsartan, aspirin.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May result in renal function deterioration, particularly in elderly or volume depleted individuals.</p></li><li>venlafaxine<p>venlafaxine, aspirin.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.</p></li><li>vorapaxar<p>aspirin, vorapaxar.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Coadministration of anticoagulants, antiplatelets, or other drug affecting coagulation should be monitored periodically due to potential increased risk of bleeding.<span><br><br></span>aspirin, vorapaxar.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive antiplatelet effect may occur.</p></li><li>vortioxetine<p>aspirin, vortioxetine.
Either increases effects of the other by anticoagulation. Use Caution/Monitor. Risk minimal with low-dose aspirin.</p></li><li>warfarin<p>warfarin and aspirin both increase  anticoagulation. Modify Therapy/Monitor Closely. The need for simultaneous use of low-dose aspirin and warfarin  are common for patients with cardiovascular disease; monitor closely.</p></li><li>zotepine<p>aspirin decreases effects of zotepine by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.</p></li>